Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Summary

This study was designed to evaluate the efficacy and safety of canakinumab administered subcutaneously every 4 weeks for at least 48 weeks in Japanese patients with Adult-Onset Still's Disease (AOSD). Interim analysis data collected at Weeks 28 and 48 supported the registration submission of canakinumab for the indication of Adult Still's Disease (ASD) in Japan.

Timeline

Start

2021-03-30

Primary completion

2025-04-16

Completion

2025-04-16

Drugs

Indications